SYNTOCINON Drug Patent Profile

« Back to Dashboard

Which patents cover Syntocinon, and when can generic versions of Syntocinon launch?

Syntocinon is a drug marketed by Novartis and Rtrx and is included in two NDAs.

The generic ingredient in SYNTOCINON is oxytocin. There is one drug master file entry for this compound. Five suppliers are listed for this compound. Additional details are available on the oxytocin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Syntocinon

A generic version of SYNTOCINON was approved as oxytocin by HIKMA on January 10^th, 2007.

Summary for SYNTOCINON

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	56
Clinical Trials:	131
Patent Applications:	3,654
DailyMed Link:	SYNTOCINON at DailyMed

Recent Clinical Trials for SYNTOCINON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Egymedicalpedia	N/A
Cairo University	NA
Cairo University	PHASE1

See all SYNTOCINON clinical trials

US Patents and Regulatory Information for SYNTOCINON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	SYNTOCINON	oxytocin	INJECTABLE;INJECTION	018245-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Rtrx	SYNTOCINON	oxytocin	SOLUTION;NASAL	012285-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Syntocinon Market Dynamics, Financial Trajectory, Competition, and Regulatory Position

Last updated: October 31, 2026

Syntocinon is a branded oxytocin injection used to induce or augment labor and to control postpartum hemorrhage. Its market is mature, volume-driven, and heavily influenced by hospital procurement rather than consumer demand. Syntocinon-specific revenue is not separately disclosed by its marketing authorization holder, so the financial analysis must rely on the economics of branded oxytocin, public procurement data, regulatory records, and broader maternal-health demand.

The commercial outlook is stable but low-growth. Demand remains structurally supported by global childbirth volumes and the clinical need to prevent or treat postpartum hemorrhage. Pricing is constrained by generic oxytocin, government tenders, essential-medicine procurement, and alternative uterotonics such as misoprostol and carbetocin. The main business risks are supply interruptions, temperature-controlled distribution, manufacturing quality, and substitution by lower-cost products.

What is Syntocinon and how is it used?

Syntocinon is a brand of oxytocin, a synthetic peptide hormone that stimulates uterine contractions. It is supplied as an injectable solution, generally in international strengths such as 5 IU/ml and 10 IU/ml, depending on the jurisdiction and presentation.

The principal uses are:

• Induction of labor.
• Augmentation of labor when contractions are inadequate.
• Management of postpartum hemorrhage caused by uterine atony.
• Facilitation of placental delivery and uterine contraction after childbirth.

The product is administered in hospitals, maternity units, operating theaters, and emergency obstetric settings. It is not a retail prescription product with significant direct-to-consumer sales.

UK product information identifies Syntocinon as an oxytocin injection marketed by Novartis Pharmaceuticals UK Limited. Product ownership, marketing authorization, and distribution arrangements can differ by country. The underlying active ingredient is widely available from multiple manufacturers, which limits the ability of the Syntocinon brand to maintain premium pricing.

How large is the Syntocinon and oxytocin market?

Syntocinon-specific market size and revenue are not publicly reported. Novartis does not separately disclose Syntocinon sales in its group financial statements, and public market reports generally combine branded oxytocin, generic oxytocin, and related uterotonic products.

The relevant market is best assessed through demand drivers:

Market driver	Effect on Syntocinon
Global births	Supports recurring baseline demand
Postpartum hemorrhage burden	Supports use in obstetric emergency care
Generic oxytocin	Reduces price and market share
Public procurement	Shifts purchasing toward lowest-cost qualified suppliers
Cold-chain requirements	Raises logistics and inventory costs
Carbetocin and misoprostol	Create therapeutic substitution risk
Hospital protocols	Can preserve use where Syntocinon is listed or familiar
Manufacturing shortages	Can increase short-term demand for available branded supply

The World Health Organization identifies uterotonics as central to postpartum hemorrhage prevention and treatment. Oxytocin remains a standard uterotonic when quality-assured and stored correctly, although alternatives are used when refrigeration, supply, or administration conditions limit its practicality (World Health Organization, 2017).

What is the financial trajectory for Syntocinon?

Syntocinon is best characterized as a mature, low-growth pharmaceutical brand rather than a growth asset.

Its financial trajectory has four components:

1. Stable clinical demand. Oxytocin is embedded in obstetric practice and is used across both high-income and emerging markets.
2. Declining pricing power. Multiple generic suppliers compete for hospital and government contracts.
3. Limited brand-driven expansion. The product has no major lifecycle strategy comparable with specialty medicines, biologics, or patented delivery systems.
4. Exposure to supply economics. Revenue and margin can fluctuate with procurement wins, shortages, manufacturing costs, and country-specific reimbursement.

A reasonable commercial model is flat-to-low-single-digit underlying volume growth, with revenue growth often constrained by price erosion. This is an analytical market characterization rather than a reported Syntocinon forecast because standalone brand revenue is not disclosed.

Revenue exposure by customer type

Customer segment	Commercial characteristics
Public hospitals	Large volumes, tender pricing, strict supply requirements
Private hospitals	Greater potential for branded purchasing, but generic substitution remains easy
Government maternal-health programs	Price-sensitive and often donor- or tender-funded
Wholesalers	Require reliable availability and regulatory-compliant stock
Emergency obstetric services	Value availability and quality over brand differentiation

The strongest commercial positions generally arise from reliable supply, established regulatory registrations, and inclusion in hospital formularies. Brand recognition alone has limited value because clinicians can use equivalent oxytocin products when procurement systems permit substitution.

What patents protect Syntocinon?

Syntocinon has little meaningful remaining composition-of-matter patent protection. Oxytocin is an old active pharmaceutical ingredient, and the commercial protection surrounding the brand is primarily regulatory and trademark-based rather than patent-based.

The relevant protection categories are:

Protection category	Current relevance
Oxytocin composition patent	Effectively exhausted for a product of this age
Basic injectable formulation patent	Generally expired or commercially immaterial
Brand trademark	Important for product identity and source recognition
Manufacturing know-how	Relevant to peptide synthesis, sterility, stability, and quality control
Regulatory approvals	Relevant on a country-by-country basis
Packaging and presentation	Limited differentiation and generally weak exclusionary value

Syntocinon does not have the patent profile of a recently launched small molecule. Its competitive defense depends on regulatory compliance, manufacturing quality, distribution, procurement relationships, and supply reliability.

What is the FDA and Orange Book status of Syntocinon?

Syntocinon is not the principal U.S. brand used for oxytocin. The U.S. market uses oxytocin injection products, including generic products and the historical brand Pitocin.

The FDA-approved oxytocin market is therefore relevant to Syntocinon’s active ingredient but does not establish U.S. exclusivity for the Syntocinon brand. Oxytocin injection is an established generic product, and the U.S. market does not provide a meaningful patent-based barrier to generic competition.

Syntocinon’s regulatory position must be evaluated separately in each jurisdiction. A marketing authorization in the United Kingdom, Europe, or another country does not create automatic approval in the United States.

When does Syntocinon lose exclusivity?

Syntocinon’s meaningful product exclusivity has already expired in the economic sense. The brand may retain trademark rights and active marketing authorizations, but oxytocin is available from multiple manufacturers.

There is no commercially significant period of remaining market exclusivity comparable with:

• New chemical entity exclusivity.
• Pediatric exclusivity.
• Orphan-drug exclusivity.
• Patent-protected formulation exclusivity.
• Biologic reference-product exclusivity.

The timing of generic entry is therefore not the key issue. Generic competition is already established in major pharmaceutical markets. The relevant commercial question is whether a specific supplier can maintain qualified supply, win tenders, and meet local regulatory requirements.

Are there formulation patents or method-of-use patents?

No major active formulation or method-of-use patent barrier is central to the Syntocinon market.

Oxytocin’s therapeutic uses, including labor induction and prevention or treatment of postpartum hemorrhage, are longstanding clinical applications. Method-of-use patents for these indications would generally face substantial validity and enforceability challenges because of the age and established use of the active ingredient.

Formulation differentiation is also limited. The main technical issues are:

• Peptide stability.
• Sterility assurance.
• Container closure integrity.
• Storage temperature.
• Protection from light and excessive heat.
• Compatibility with infusion systems.

These issues can create quality and supply barriers without creating meaningful patent exclusivity.

How strong is the Syntocinon patent estate?

The patent estate is weak as a commercial exclusion tool. Its strength lies in operational execution rather than patent claims.

Factor	Assessment
Composition-of-matter protection	None of practical significance
Formulation exclusivity	Low
Method-of-use exclusivity	Low
Trademark protection	Moderate for brand identity
Manufacturing barriers	Moderate, especially for sterile injectable production
Regulatory barriers	Moderate to high in individual jurisdictions
Supply-chain differentiation	Potentially meaningful
Generic substitution risk	High

The most defensible assets are manufacturing know-how, validated sterile production, regulatory files, supplier qualifications, and distribution capacity. Those assets can support market participation but do not prevent competitors from selling oxytocin.

Which companies challenge Syntocinon?

Competition comes primarily from generic manufacturers rather than from companies pursuing patent litigation against the brand.

Competitive products include:

• Generic oxytocin injections.
• Pitocin and other oxytocin products in the United States.
• Carbetocin products for selected postpartum hemorrhage settings.
• Misoprostol products where refrigeration or injectable administration is difficult.
• Other locally approved uterotonics.

The supplier landscape differs by country. In public markets, companies compete through tender price, reliability, regulatory status, manufacturing location, and the ability to maintain supply during shortages.

There is no widely reported, commercially material Paragraph IV litigation campaign centered on Syntocinon. Because oxytocin’s core intellectual property is long expired, generic entry does not depend on challenging a live Syntocinon patent estate.

What manufacturing and supply risks affect Syntocinon?

Manufacturing and distribution are more important than patent protection.

Oxytocin is sensitive to temperature and requires controlled storage. The WHO has identified quality and storage concerns affecting oxytocin supply, particularly in settings where cold-chain infrastructure is weak. Degradation can reduce potency and create clinical risk if the product is improperly handled (World Health Organization, 2017).

Key barriers include:

• Sterile injectable manufacturing capacity.
• Quality control for peptide potency.
• Reliable active-ingredient supply.
• Cold-chain distribution.
• Batch-release testing.
• Regulatory inspections.
• Hospital inventory management.
• Shortage-related allocation decisions.

These factors can produce temporary pricing opportunities for an available supplier. They do not create durable monopoly economics because competing manufacturers can enter when regulatory and manufacturing requirements are satisfied.

How does Syntocinon compare with carbetocin and misoprostol?

Product	Main advantage	Main limitation	Competitive effect on Syntocinon
Syntocinon or generic oxytocin	Established standard; broad clinical familiarity	Requires injection and temperature control	Baseline competitor and reference product
Carbetocin	Longer-acting uterotonic; useful in selected protocols	Higher cost and narrower economic access	Substitution risk in selected hospital settings
Misoprostol	Oral or other non-injectable administration; easier storage	Different adverse-effect and efficacy profile	Strong substitute where refrigeration is difficult
Ergometrine-containing products	Established uterotonic option	Contraindications limit use	Supplemental rather than universal substitute

WHO guidance supports selection based on clinical context, availability, storage, contraindications, and cost. Syntocinon remains well positioned where injectable oxytocin is available and included in standard obstetric protocols, but it is vulnerable in low-resource settings where storage and administration constraints favor misoprostol or heat-stable products.

What litigation and settlement risks affect Syntocinon?

No major publicly recognized patent litigation or settlement agreement is central to Syntocinon’s present commercial outlook. The absence of a live patent dispute is consistent with the product’s age and generic market structure.

The principal legal risks are more likely to involve:

• Product liability.
• Manufacturing-quality investigations.
• Regulatory noncompliance.
• Supply-contract disputes.
• Trademark conflicts.
• Procurement challenges.
• National reimbursement and tender decisions.

These risks can affect individual markets without changing the global competitive structure.

What generic launch scenarios exist for Syntocinon?

Generic launch risk is already realized rather than prospective.

Base case

Generic oxytocin retains most volume in tender-driven markets. Syntocinon remains in selected hospital formularies where brand familiarity, supply reliability, or local contracting supports continued use.

Downside case

Price competition intensifies, public buyers consolidate procurement, and Syntocinon loses formulary position. Revenue declines faster than underlying childbirth volumes.

Supply-disruption case

Manufacturing interruptions among generic suppliers temporarily increase demand for Syntocinon or other branded products. This can lift short-term volume but may not produce durable market-share gains.

Differentiation case

A reformulated or heat-stable oxytocin product gains adoption in markets with weak cold-chain infrastructure. The opportunity would depend on regulatory approval, clinical validation, and procurement economics rather than legacy Syntocinon branding.

What is the geographic coverage of Syntocinon?

Syntocinon has historically been associated with markets outside the United States, including the United Kingdom and other international jurisdictions. Product availability, marketing authorization, strength, packaging, and local rights vary by country.

Geographic performance depends on:

• National maternal-health policy.
• Hospital procurement systems.
• Local regulatory registration.
• Cold-chain infrastructure.
• Generic competition.
• The presence of local manufacturers.
• Reimbursement and tender rules.

The brand’s strongest value is likely in markets where it has long-standing regulatory status and established hospital use. In low-income settings, branded share is generally more vulnerable to procurement price pressure and donor-funded purchasing.

Key Takeaways

• Syntocinon is a mature oxytocin brand used mainly in hospital obstetric care.
• Standalone Syntocinon revenue is not publicly disclosed.
• The financial trajectory is likely stable to low-growth in volume, with significant price pressure.
• Oxytocin has no meaningful remaining composition-of-matter exclusivity.
• The principal competitive barriers are sterile manufacturing, quality control, regulatory approval, and supply reliability.
• Generic oxytocin is the primary commercial threat.
• Carbetocin and misoprostol create substitution risk in specific clinical and logistics settings.
• No major Paragraph IV campaign, patent litigation, or settlement is central to the product’s present market outlook.
• Cold-chain requirements and supply interruptions can cause short-term market-share changes.
• Syntocinon is better assessed as a reliable mature hospital brand than as a patent-protected growth product.

FAQs

Is Syntocinon the same as oxytocin?

Yes. Syntocinon is a branded injectable product containing synthetic oxytocin. Generic oxytocin injections contain the same active ingredient but are manufactured and marketed by different companies.

Is Syntocinon still under patent?

No commercially meaningful patent exclusivity remains for the core oxytocin product. Trademark, regulatory approval, manufacturing know-how, and supply arrangements are more relevant than patent protection.

Does Syntocinon have a U.S. market?

The United States primarily uses oxytocin injection products such as generic oxytocin and Pitocin. Syntocinon is not the principal U.S. brand for the active ingredient.

Can hospitals substitute generic oxytocin for Syntocinon?

Substitution depends on national law, hospital formularies, procurement contracts, product approval, and clinical protocols. Where an approved generic is available, substitution is generally commercially feasible.

Is carbetocin a direct replacement for Syntocinon?

Carbetocin can be used as an alternative uterotonic in selected postpartum hemorrhage protocols, but it is not universally interchangeable with oxytocin. Clinical indication, cost, formulation, storage, and local guidelines determine product selection.

References

1. Novartis Pharmaceuticals UK Limited. (n.d.). Syntocinon 10 IU/ml solution for injection or infusion: Summary of product characteristics. Electronic Medicines Compendium.

2. U.S. Food and Drug Administration. (n.d.). Oxytocin injection prescribing information. FDA.

3. World Health Organization. (2017). WHO recommendations: Uterotonics for the prevention of postpartum haemorrhage. World Health Organization.

4. World Health Organization. (2012). WHO recommendations for the prevention and treatment of postpartum haemorrhage. World Health Organization.

5. Novartis AG. (2023). Annual report 2023. Novartis.